NY-CLARITY-AI
29.10.2020 14:02:13 CET | Business Wire | Press release
Clarity AI announced today that it has closed a USD $15 million funding round led by Deutsche Börse AG and co-investor Mundi Ventures. Clarity AI empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders.
“Our purpose is simple: to measure the impact of companies on our society and planet,” said Rebeca Minguela, Founder and CEO of Clarity AI. “Investors attempting to evaluate impact have faced fragmented and unreliable data, inconsistent subjective definitions, and a lack of standards and tools for comprehensive analysis. Historically it has been too hard and resource-intensive to get accurate and transparent insights. Clarity AI provides a solution for that.”
Since its founding in 2017, Clarity AI has attracted a client network representing in excess of $3 trillion of assets and funding from investors, including Kibo Ventures, Founders Fund, Seaya Ventures and Matthew Freud. The company has built the most reliable tech platform on social and environmental impact, featuring more than 30,000 companies, 198 countries, 187 local governments and over 200,000 funds. The company uses proprietary technology and algorithms to produce transparent assessments for investors that are the most consistent and comprehensive available.
The “Sustainable Investment” market has grown 34% in the last two years and now represents one third of total global assets under management (AUM) – $30.7 trillion (of a total of $79.2 trillion).1 This rapid growth comes as research shows that 81% of investors want to better understand and improve the impact performance of their investments, with millennials (in particular) demanding greater social impact transparency in their portfolios.2
In the last six months, Clarity AI has seen a significant increase in demand for its services, including signing clients with eight times the assets under management as in the preceding period.
Minguela added: “2020 has seen extraordinary volatility and uncertainty – from COVID-19 to social justice protests. It has never been more important for investors to have accurate insights on the true impact of the companies in which they place their trust and their money. That is why we are scaling up our business to enable investors to identify and support those companies helping to solve society’s biggest challenges.”
The $15 million investment will drive Clarity AI’s sustainable expansion plans, including scaling-up investment in proprietary technology and AI, as well as integrating with the world’s largest financial services platforms. This approach will make it even quicker and easier for investors and corporations to analyze and report sustainability and impact.
Deutsche Börse AG led the funding round, underscoring the strong alignment of the Clarity AI product offering with Deutsche Börse’s expanding presence in the sustainability space and the importance of accelerating the growth of a European-focused Impact and ESG technology platform. Clarity AI and Deutsche Börse are also exploring potential collaboration opportunities in various Deutsche Börse business areas, including Qontigo, a leading provider of indices and analytics.
Sebastian Ceria, CEO of Qontigo, said: “This partnership reflects our mutual commitment to the ongoing enhancement of sustainable investing and the application of the latest technology in pursuit of this goal. We were very impressed by Rebeca and her team’s vision for Clarity AI and the advanced technology platform they have created. We are excited to be in a partnership that puts impact at the heart of investment.”
Clarity AI has received widespread recognition for its positive impact and innovative approach, including being selected as a 2020 Technology Pioneer by the World Economic Forum and receiving awards from the Harvard Innovation Lab and funding from Horizon 2020, the European Union’s Research and Innovation program.
Ends
NOTE TO EDITORS
ABOUT CLARITY AI
Clarity AI is a global fintech company that empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders. Founded in 2017 by Rebeca Minguela, Clarity AI has offices in the US, UK and Spain and a client network with over $3T assets under management (AUM). The company has a team of over 100 technology, sustainability and research experts with collective experience from leading organizations, businesses and research institutions including NASA, the World Bank, Google, Netflix, McKinsey & Company, Morgan Stanley, J.P. Morgan, Harvard, M.I.T and more.
Rebeca Minguela is the Founder and CEO of Clarity AI. Previously, she led the Global Digital Transformation Program at Santander Bank after founding and leading Blink Booking, a last-minute hotel booking app acquired by Groupon in 2013, a company she moved to as Senior Director of Product and Technology thereafter. Rebeca has also worked at Bain Capital Private Equity, Boston Consulting Group, German Aerospace Agency, Siemens and IBM. She holds an MBA degree with distinction from Harvard Business School and has won several awards, including Top 25 Women Leaders in Financial Technology in 2019 and 2020, Young Global Leader by the World Economic Forum in 2017 and European Young Leader in 2018.
For more information, visit https://clarity.ai/
ABOUT DEUTSCHE BÖRSE
As an international exchange organisation and innovative market infrastructure provider, Deutsche Börse Group ensures markets characterised by integrity, transparency and stability. With its wide range of products, services and technologies, the Group organises safe and efficient markets for sustainable economies.
Its business areas extend along the entire value chain in exchange trading, including the admission, trading and clearing, and custody of securities and other financial instruments, the dissemination of market data, as well as the management of collateral and liquidity. As a technology company, the Group develops state-of-the-art IT solutions and offers IT systems all over the world.
With around 6,000 employees, the Group has its headquarters in the financial centre of Frankfurt/Rhine-Main, as well as a strong global presence in 38 locations such as Luxembourg, Prague, London, New York, Chicago, Hong Kong, Singapore, Beijing, Tokyo and Sydney.
ABOUT ALMA MUNDI VENTURES
Alma Mundi is a Venture Capital fund investing in B2B tech and Insurtech startups across Europe, the United States and Israel. The investments range from early Seed and Series A, to Series B and later stages. The headquarters are in Madrid and offices in Barcelona, London and Tel Aviv. The portfolio includes startups in London, Paris, Amsterdam, Berlin, Tel Aviv, San Francisco and New York. They bring value to entrepreneurs by leveraging their LPs, leading European insurers, and a global network, called the Mundi Club, which groups more than 750 C-level executives in more than 50 cities worldwide.
1
Gl
obal Asset Management 2018: The Digital Metamorphosis, https://www.bcg.com/publications/2018/global-asset-management-2018-digital-metamorphosis
; Global Sustainable Investment Alliance: 2018 Global Sustainable Investment Review, http://www.gsi-alliance.org/wp-content/uploads/2019/03/GSIR_Review2018.3.28.pdf
2
Har
vard Law School Forum on Corporate Governance: Institutional Investor Survey 2020, https://corpgov.law.harvard.edu/2020/03/25/institutional-investor-survey-2020/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
